AFP and neoplasm: This result indicated that FOLFOX-HAIC had a higher probability of being cost-effective for patients with age ≤50 years, alpha-fetoprotein (AFP) >400 ng/ml, tumor number ≤3, Child–Pugh grade A (5 points), ECOG score of 0, tumor size >10 cm, and positive hepatitis B infection.